Pfizer, Beqvez and The Nikkei
Prolific NYC real estate investor David Werner has finally completed the complex real estate puzzle underpinning his planned ...
Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...
Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's ...
Challenging powerhouse Pfizer, BridgeBio's launch of Attruby is off to a 'great start,' analyst says
An intriguing battle is brewing in the market to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM). | BridgeBio reported that 1,028 unique prescriptions have been written by 516 ...
Pfizer's robust R&D pipeline is expected to drive future growth and offset patent expirations. Read why I maintain my buy ...
All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...
Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...
Pfizer Inc. closed 19.06% short of its 52-week high of $31.54, which the company reached on July 30th.
Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.
1h
Latin Times on MSNPfizer Exec Booed During White House Appearance as Trump Calls Pharma Head 'Great Businessman'President Donald Trump's introduction of a Pfizer executive at the White House Wednesday was met with a roar of boos from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results